Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 15/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 12/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.38 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3328811 | 0.90 | PIK3CA (0.43) | PIK3CAPIK3R1PIK3CDPIK3CBMAPK1 | |
| SCHEMBL244726 | 0.77 | PIK3CA (0.40) | PIK3CAPIK3R1KCNQ3KCNQ2MAPK1 | |
| SCHEMBL14803578 | 0.76 | ADORA2A (0.47) | PIK3CAPIK3R1PIK3CDPIK3CBKCNQ3 | |
| SCHEMBL243285 | 0.74 | PIK3CA (0.40) | PIK3CAPIK3R1MTOR | |
| SCHEMBL3108283 | 0.72 | PIK3CA (0.42) | PIK3CAPIK3R1PIK3CDPIK3CBMAPK1 | |
| SCHEMBL243583 | 0.69 | PIK3CA (0.43) | PIK3CAPIK3R1PIK3CDPIK3CBKCNQ3 | |
| SCHEMBL3118679 | 0.67 | PIK3R1 (0.41) | PIK3CAPIK3R1PIK3CDPIK3CB | |
| SCHEMBL1458406 | 0.66 | PIK3CA (0.54) | PIK3CAPIK3R1PIK3CDPIK3CBMTOR | |
| SCHEMBL3994283 | 0.65 | LMNA (0.41) | PIK3CAPIK3CDPIK3CBMTOR | |
| SCHEMBL3342182 | 0.65 | GPR119 (0.41) | PIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588473-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS PIK3 -DELTA INHIBITORS | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130079342-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. | 2013-03-28 | — | — | US | disclosed |
| WO-2012003264-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS PIK3 -DELTA INHIBITORS | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079342-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CA 26/4885PIK3R1 56/4885PIK3CD 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.